摘要
目的探讨基因多态性诊断芯片在拉米夫定治疗慢性乙型肝炎中乙肝病毒YMDD变异与HBV-DNA及ALT水平变化的临床意义。方法利用基因芯片、ELISA及生化检测技术检测360例慢性乙肝患者服用拉米夫定4～24个月后YMDD变异、HBV-DNA及ALT水平变化。结果360例患者中,335例患者的HBV-DNA及ALT出现不同程度下降,其中56例(15.5%)的YMDD出现变异,同时HBV-DNA及ALT水平出现反跳。结论服用拉米夫定的慢性乙肝患者的YMDD变异与服药时间长短有关,血清中HBV-DNA及ALT与YMDD相关,所以在应用拉米夫定是需定时监测YMDD突变,若出现耐药突变后继续服用拉米夫定对耐药株无效,应根据患者的个体情况改用其它抗病毒药物治疗。
OBJECTIVE To explore the relationship between YMDD mutation, HBV-DNA determination, ALT level and chronic hepatic B patients with lamivudine. METHODS 360 patients with lamivudine was measured by gene-chip, ELISA and autobiological analyzer. RESULTS HBV-DNA and ALT levels in 355 patients were decreased, YMDD mutations were found in 56 （15.5%） patients, but the levels of HBV-DNA and ALT were rebounced. CONCLUSION Our results indicated that YMDD mutation, HBV-DNA determination, ALT level changed with treatment duration. If YMDD mutated, anti-virus drug should be altered.
出处
《齐鲁药事》
2007年第2期98-99,共2页
qilu pharmaceutical affairs
关键词
拉米夫定
YMDD变异
基因芯片
HBV—DNA
ALT
Lamivudine
YMDD mutation
gene chip
HBV-DNA determination
alanine amino transferase （ALT）
